Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBIT Margin (2020 - 2025)

Historic EBIT Margin for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 2.78%.

  • GeneDx Holdings' EBIT Margin rose 73400.0% to 2.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.48%, marking a year-over-year increase of 240600.0%. This contributed to the annual value of 7.6% for FY2024, which is 815500.0% up from last year.
  • Per GeneDx Holdings' latest filing, its EBIT Margin stood at 2.78% for Q3 2025, which was up 73400.0% from 8.73% recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' EBIT Margin ranged from a high of 9.21% in Q4 2024 and a low of 529.56% during Q4 2022
  • Over the past 5 years, GeneDx Holdings' median EBIT Margin value was 96.67% (recorded in 2021), while the average stood at 129.99%.
  • As far as peak fluctuations go, GeneDx Holdings' EBIT Margin crashed by -3530200bps in 2022, and later surged by 4848900bps in 2023.
  • Quarter analysis of 5 years shows GeneDx Holdings' EBIT Margin stood at 200.31% in 2021, then crashed by -164bps to 529.56% in 2022, then skyrocketed by 92bps to 44.66% in 2023, then skyrocketed by 121bps to 9.21% in 2024, then tumbled by -130bps to 2.78% in 2025.
  • Its last three reported values are 2.78% in Q3 2025, 8.73% for Q2 2025, and 5.22% during Q1 2025.